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Background: ODM-201, a new androgen receptor antagonist for treatment of metastatic
castration-resistant prostate cancer (mCRPC), demonstrated antitumour activity and accept-
able tolerability in phase 1/2 trials.
Objective: To determine the antitumour activity and safety proﬁle of extended treatment with
ODM-201 in men with mCRPC.
Design, setting, and participants: ARADES and ARAFOR trials with ODM-201 enrolled chemo-
therapy-naïve and CYP17 inhibitor (CYP17i)-naïve mCRPC patients. Both trials had extended
follow-up. Here we report results for chemotherapy-naïve and CYP17i-naïve patients from both
trials (data cutoff October 2014 for ARADES and April 2015 for ARAFOR) after extended follow-up.
Intervention: A total of 41 chemotherapy-naïve and CYP17i-naïve patients received oral ODM-
201 twice daily (total daily dose of 1200, 1400 or 1800 mg).
Outcome measurements and statistical analysis: Antitumour activity was assessed in terms
of prostate-speciﬁc antigen (PSA) declines and PSA/radiographic progression. Safety was
assessed until disease progression and/or drug discontinuation due to any intolerable adverse
event (AE).
Results and limitations: ODM-201 safety data after a median treatment time of 13.5 mo (95%
conﬁdence interval [CI] 9.7–15.6, interquartile range [IQR] 7.5–22.0) were similar to those
reported in the main ARADES and ARAFOR trials. The overall AE incidence was 80.5% (n = 33/41),
with 58.5% (n = 24/41) of patients experiencing only grade 1–2 AEs. The most common AEs were
fatigue, back pain, diarrhoea, nausea, and pain in extremity. The median times to PSA
and radiological progression were 12.4 mo (95% CI 6.3–18.2, IQR 5.5–22.0) and 15.3 mo
(95% CI 9.5–not reached [NR], IQR 6.3–NR), respectively.
Conclusions: Extended treatment with ODM-201 (1200–1800 mg/d) was well tolerated, with
no new safety concerns, and provided evidence of sustained antitumour activity in chemotherapy-
naïve and CYP17i-naïve patients with mCRPC.
Patient summary: Prolonged treatment with high doses of ODM-201 was well tolerated and
provided long-lasting disease control in patients with mCRPC. ODM-201 represents a thera-
peutic treatment option for mCRPC.
The ARAFOR trial (including the follow-up stage) and the follow-up component of the
ARADES trial are registered with ClinicalTrials.gov as trial numbers NCT01784757 and
NCT01429064.iat
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Prostate cancer (PCa) is the third most common cause of
cancer-related death in men in the EU, with an estimated
92 000 deaths in 2012 [1]. Androgen deprivation therapy
(ADT), via either orchiectomy or treatment with a luteinis-
ing hormone–releasing hormone agonist/antagonist, is the
standard of care for patients with hormone-sensitive
advanced PCa [2,3]. Despite an initial response to treatment,
most patients progress to metastatic castration-resistant
PCa (mCRPC), which has a poor prognosis [2,4,5] and
requires subsequent therapeutic intervention [6,7].
Alterations in the androgen receptor (AR) signalling
pathway are the main underlying molecular mechanism
driving mCRPC [8–10]. As tumour growth of PCa cells in
the castration-resistant disease stage is dependent on per-
sistent AR signalling, the AR axis is considered an effective
therapeutic target in mCRPC [11,12]. Specific androgen axis-
and AR-targeting agents—abiraterone and enzalutamide—
have been approved in the EU and the USA for mCRPC
treatment. Both compounds improved overall survival
and radiographic progression-free survival and had a bene-
ficial impact on quality of life (QoL) in phase 3 trials includ-
ing post-chemotherapy [13–15] and pre-chemotherapy
[16,17] mCRPC patients. New AR inhibitors are being devel-
oped for treatment of mCRPC, including ODM-201, an inves-
tigational nonsteroidal oral AR antagonist that is structur-
ally different from any other antiandrogen compound,
including enzalutamide and apalutamide [18]. A preclinical
study showed that ODM-201 has antitumour activity in
vivo, as it inhibited tumour growth in a murine VCap CRPC
xenograft model, with higher activity than enzalutamide
[18].
In two phase 1/2 trials, ODM-201 exhibited antitumour
activity and was well tolerated in men with mCRPC. In
the open-label multicentre ARADES trial (NCT01429064),
a non-randomised, first-in-man, dose escalation phase 1
(n = 24) showed that antitumour activity was achieved at
all doses tested (200–1800 mg/d) and no dose-limiting
toxicity was observed [19]. In the phase 2 extension
(n = 110), a prostate-specific antigen (PSA) decline was
observed with all ODM-201 doses tested (200–1400 mg/d),
and the 1400-mg/d dose led to the greatest PSA response in
chemotherapy-naïve and CYP17 inhibitor (CYP17i)-naïve
patients. Furthermore, ODM-201 was well tolerated, with
>99% of adverse events (AEs) being grade 1–2 [19].
ARAFOR (NCT01784757) was an open-label multicentre
trial that included a pharmacokinetic component (n = 30)
and an open-label extension study (n = 30) [20]. ODM-201
demonstrated antitumour activity and was well tolerated
in chemotherapy-naïve patients: a PSA response (50%
decrease in PSA levels from baseline at week 12) was
observed in 25/30 patients (83%), and 91% of treatment-
emergent AEs were of grade 1–2 [20].
With the previous findings from the ARADES and
ARAFOR trials, the safety and tumour-suppression activity
of extended ODM-201 dosing in men with mCRPC are of
clinical interest, as these patients usually benefit from
prolonged treatment. Here we report data from thefollow-up of the ARADES and ARAFOR trials on the safety
and antitumour activity of ODM-201 in patients with
mCRPC, who did not receive prior chemotherapy or CYP17i.
2. Patients and methods
2.1. Study design and patients
The data presented here from the ARADES (cutoff date October 31, 2014)
[19] and ARAFOR (cutoff date April 30, 2015) trials [20] include those
patients who were chemotherapy- and CYP17i-naïve and received 1200,
1400 or 1800 mg/d of ODM-201. The complete study design was
published previously [19,20]. In brief, male patients were aged 18 yr,
had progressive mCRPC, an Eastern Cooperative Oncology Group perfor-
mance status (ECOG-PS) score of 0–1, and serum testosterone levels
<1.7 nmol/l. Patients were included if they were mildly symptomatic or
asymptomatic and those with a history or risk of seizures could be
included. Patients without bilateral orchidectomy had to continue
approved ADT during the trial.
In the ARADES and ARAFOR trials, disease progression was deﬁned
by: rising PSA (two consecutive increases in PSA levels 1 wk apart, with
the lowest value being 2 ng/ml); radiographic disease progression
(assessed using the modiﬁed Response Evaluation Criteria in Solid
Tumours version 1.1); or the presence of two or more new bone lesions.
Exclusion criteria were the presence of brain metastases and prior
treatment with AR antagonists, CYP17i or chemotherapy.
2.2. Ethics
Patients gave written informed consent and the trials were approved by
an independent ethics committee at each centre or by the investigational
review board. The trials were conducted according to the principles of
the Declaration of Helsinki and the guidelines for Good Clinical Practice.
2.3. Treatment
Patients received ODM-201 twice daily with food (total daily dose of
1200, 1400 or 1800 mg). Treatment continued until disease progression
or an intolerable AE.
2.4. Antitumour activity assessments
In the ARADES and ARAFOR trials, PSA concentrations were measured at
baseline, every 4 wk until the 9-mo visit, every 3 mo thereafter, and at
the end-of-study visit. The percentage change in serum PSA was calcu-
lated from baseline until patients discontinued the study. Baseline PSA
was deﬁned as the PSA level before the ﬁrst ODM-201 dose.
The median time to PSA progression was deﬁned as the time from
ODM-201 treatment initiation until documentation of a 25% increase
and an absolute increase of 2 ng/ml in PSA from nadir, according to
Prostate Cancer Working Group 2 criteria [21]; this had to be conﬁrmed
by an additional PSA measurement 3 wk later. A minimum period of
12 wk was required before PSA progression could be declared. Time to
radiographic progression was deﬁned as the time between the start of
treatment and the occurrence of the ﬁrst progression (soft tissue or
bone) as assessed using computed tomography/magnetic resonance
imaging or a bone scan.
2.5. Safety and tolerability
AEs were classiﬁed by system organ classes and preferred terms (Medical
Dictionary for Regulatory Activities coding system, version 17.1 in the
ARADES trial, and 18.0 in the ARAFOR trial) and graded by the National
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Laboratory assessments (haematology, serum biochemistry, hormones
and urine analysis) were performed: at baseline, once a week for the ﬁrst
28 d, every 4 wk until the 9-mo visit, every 3 mo thereafter, and at
the end-of-study visit. Hormone measurements were performed up to
week 12.
2.6. Statistical analysis
Antitumour activity and safety analyses included all patients who
received at least one dose of ODM-201. Time to PSA and radiographic
progression were calculated using Kaplan-Meier estimates; the median
values with associated 95% conﬁdence intervals (CIs) and interquartile
ranges (IQRs) are reported. All measurements are summarised using
descriptive statistics. Analyses were performed using data collected up




A total of 41 patients with progressive mCRPC were
included in the analyses; they were all chemotherapy-naïveTable 1 – Baseline demographics and clinical characteristics.
ARADES trial (n = 11) 
Age (yr) 73.0 (62.0–82.0) 
PSA (ng/ml) 219.2 (14.9–1293.8) a
Testosterone (ng/dl) 0.7 (0.4–1.7) 
LDH (U/l) 193.0 (159.6–515.0) a
Gleason score at diagnosis
2–6 1 (9.1) 
7 4 (36.4) 
8–10 5 (45.5) 
Missing c 1 (9.1) 
ECOG-PS
0 10 (90.9) 
1 1 (9.1) 
Time from diagnosis to SS (mo) 64.1 (10.9–165.7) 
Prior antiandrogen therapy 11 (100.0) 
LHRH therapy 10 (90.9) 
Time from LHRH therapy to SS (mo) 40.7 (6.6–153.3) d
Disease localisation
Lymph node 4 (36.4) 
Bone disease 9 (81.8) 
Bone only 7 (63.6) 
Bone and soft tissue 2 (18.2) 
Soft tissue only 2 (18.2) 
Visceral 1 (9.1) 
Bone metastases at screening
0 2 (18.2) 
1–4 3 (27.3) 
5–20 3 (27.3) 
>20 or non-countable 3 (27.3) 
ECOG-PS = Eastern Cooperative Oncology Group performance status; LDH =
PSA = prostate-speciﬁc antigen; SS = study start.
Data are presented as median (range) for continuous variables and as n (%) for c
a n = 10.
b n = 40.
c Gleason score not available.
d n = 8.
e n = 29.
f n = 37.and CYP17i-naïve. Of these, 30 (73.2%) were from the
ARAFOR trial and 11 (26.8%) from the ARADES trial.
Baseline demographic and clinical characteristics of the
patients were well balanced in the two trials (Table 1). The
median age was 69.0 yr (range 54.0–86.0) and most patients
(73.2%) were classified as ECOG-PS score 0. The overall
baseline median PSA was 27.7 ng/ml (range 3.5–1293.8);
most patients had bone disease at screening (n = 36, 87.8%),
whereas 16 patients (39.0%) had disease localised in the
lymph nodes and three patients (7.3%) had visceral disease.
Data for patients from the ARADES trial were collected
until October 31, 2014; the initial results were reported in
2014 using a cutoff date of October 3, 2013 [19]. Patient data
from the ARAFOR trial were collected through to April 30,
2015 and the initial results were published in 2015 with a
cutoff date of October 31, 2014 [20]. The difference in cutoff
dates between the two studies presented here reflects the
different study initiation dates [19,20].
All patients from the ARAFOR trial (30/41, 73.2%)
received 1200 mg/d of ODM-201, while ARADES patients
received 1400 mg/d (n = 9/41, 22.0%) or 1800 mg/d (n = 2,
4.9%). Overall, 30/41 patients (73.2%) discontinued the
study; the most common cause of discontinuation wasARAFOR trial (n = 30) Total (n = 41)
68.0 (54.0–86.0) 69.0 (54.0–86.0)
18.2 (3.5–554.8) 27.7 (3.5–1293.8) b
0.8 (0.4–1.6) 0.8 (0.4–1.7)
323.5 (163.0–559.0) 287.0 (159.6–559.0) b
6 (20.0) 7 (17.1)
12 (40.0) 16 (39.0)
12 (40.0) 17 (41.5)
0 (0.0) 1 (2.4)
20 (66.7) 30 (73.2)
10 (33.3) 11 (26.8)
39.7 (7.6–133.7) 50.0 (7.6–165.7)
22 (73.3) 33 (80.5)
30 (100.0) 40 (97.6)
22.5 (0.9–126.6) e 22.5 (0.9–153.3) f
12 (40.0) 16 (39.0)
27 (90.0) 36 (87.8)
15 (50.0) 22 (53.7)
12 (40.0) 14 (34.1)
3 (10.0) 5 (12.2)
2 (6.7) 3 (7.3)
3 (10.0) 5 (12.2)
9 (30.0) 12 (29.3)
4 (13.3) 7 (17.1)
14 (46.7) 17 (41.5)
 lactate dehydrogenase; LHRH = luteinising hormone-releasing hormone;
ategorical variables.
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patients (6.7%) discontinuing due to AEs and one (3.3%)
for personal reasons. Four ARADES patients whose treat-
ment was ongoing after the original data cutoff of October 3,
2013 [19] discontinued the extension study before the new
cutoff date of October 31, 2014. Of the ten patients who were
ongoing by October 31, 2014 in the main ARAFOR trial [20],
one discontinued the extension follow-up before the new
cutoff date of April 30, 2015 and one discontinued study
treatment, but not the study, before the extended data
cutoff.
Although the median follow-up time was 15.3 mo
(95% CI 10.4–16.5, IQR 7.9–25.7; Fig. 1) and the median
on-treatment time was 13.5 mo (95% CI 9.7–15.6, IQR
7.5–22.0), 11 patients (n = 10 ARAFOR and n = 1 ARADES)
continued the study after the data cutoff. Of these, ten
patients (n = 9 ARAFOR and n = 1 ARADES) continued
ODM-201 treatment after the data cutoff: two patients
were on a named patient (compassionate) use basis, with
one patient receiving treatment until the end of August
2016, for a total on-treatment time of 41 mo.
3.2. Safety
An AE was experienced by 80.5% (n = 33/41) of patients, and
29 patients (70.7%) had more than one AE. The most com-
mon AEs of any grade were: fatigue (grade 1) in eight
patients (19.5%); nausea (grade 1–3), pain in extremityFig. 1 – Kaplan-Meier estimate of (A) follow-up and (B) time on
treatment. CI = confidence interval.(grade 1–2), back pain (grade 2–3) and diarrhoea (grade
1–2) in five patients (12.2%); and arthralgia (grade 1–2) in
four patients (9.8%) (Table 2). Overall, 24 patients (58.5%)
had only grade 1–2 AEs and seven patients (17.1%) experi-
enced grade 3 AEs, including: PCa progression, back pain,
nausea, bone pain, increase in blood alkaline phosphatase,
hypertension, hyponatraemia, lung adenocarcinoma, fall
and femoral neck fracture (Table 2). Grade 4 AEs were
observed only in the ARAFOR trial and included respiratory
failure and neuroendocrine carcinoma (two patients), and
one patient died due to general physical health deteriora-
tion and PCa progression (Table 2). The pattern of AEs
reported during this study in chemotherapy-naïve and
CYP17i-naïve patients is similar to that reported in the same
patient population during the main ARADES and ARAFOR
trials: at the time of the original cutoff dates (October 3,
2013 for ARADES and October 31, 2014 for ARAFOR), the
most common AEs of any grade included grade 1 fatigue/
asthenia (8 patients, 19.5%); diarrhoea and pain in extremity
(grade 1–2) and grade 1–3 nausea (5 patients, 12.2%); and
grade 2–3 back pain and grade 1–2 peripheral oedema
(4 patients, 9.8%). Furthermore, during the main ARADES
and ARAFOR trials the incidence of grade 3 AEs (4 patients,
9.8%) was similar to that reported during the follow-up
(7 patients, 17.1%); overall, no new AEs (any grade) were
observed in the follow-up.
During this study, treatment-related AEs occurred in
ten patients (24.4%): four patients (36.4%) were from the
ARADES trial and six (20.0%) from ARAFOR (Table 3). All
treatment-related AEs were grade 1; the most common were
fatigue (3 patients, 7.3%) and hot flush (2 patients, 4.9%).
3.3. Antitumour activity
The percentage PSA change from baseline for each patient
during treatment with 1200, 1400, and 1800 mg/d of
ODM-201 is shown in Fig. 2A. The maximum PSA response
rate (50% PSA reduction from baseline at any time during
the study) was 85% (n = 34/40); this was 80% (n = 8/10) and
87% (n = 26/30) in the ARADES and ARAFOR trials, respec-
tively (Fig. 2B).
The median time to PSA progression was 12.4 mo (95% CI
6.3–18.2, IQR 5.5–22.0) for all patients (Fig. 2C). This was
slightly longer in the ARAFOR trial (12.5 mo, 95% CI 5.4–not
reached [NR], IQR 4.6–NR) than in the ARADES trial (9.9 mo,
95% CI 5.5–22.0, IQR 7.6–19.6). Similar data were obtained for
the time to radiological progression; this was 15.3 mo (95% CI
9.5–NR, IQR 6.3–NR) in the ARAFOR trial, but was not reached
in the ARADES trial (95% CI 2.6–NR, IQR 14.0–NR).
4. Discussion
Analysis of the extended follow-up of patients from the
ARADES and ARAFOR trials indicated that for up to 25.7 mo
(median 15.3), treatment with high doses of ODM-201
(1200, 1400 and 1800 mg/d) was well tolerated and pro-
vided durable antitumour activity in chemotherapy-naïve
and CYP17i-naïve patients with mCRPC. These results are
consistent with the findings reported for the earlier stages
Table 2 – Adverse events (AEs).
Patients reporting AEs, n (%)
Grade 1–2 Grade 3 Grade 4 Grade 5
Any AEs
ARADES (n = 11) 11 (100.0) 1 (9.1) 0 (0.0) 0 (0.0)
ARAFOR (n = 30) 21 (70.0) 6 (20.0) 2 (6.7) 1 (3.3)
Total (n = 41) 32 (78.0) 7 (17.1) 2 (4.9) 1 (2.4)
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Grades 1–5
Common AEs a (n = 41)
Fatigue 8 (19.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 8 (19.5)
Nausea 4 (9.8) 1 (2.4) 1 (2.4) 0 (0.0) 0 (0.0) 5 (12.2)
Pain in extremity 5 (12.2) 1 (2.4) 0 (0.0) 0 (0.0) 0 (0.0) 5 (12.2)
Back pain 0 (0.0) 4 (9.8) 1 (2.4) 0 (0.0) 0 (0.0) 5 (12.2)
Diarrhoea 4 (9.8) 1 (2.4) 0 (0.0) 0 (0.0) 0 (0.0) 5 (12.2)
Arthralgia 2 (4.9) 2 (4.9) 0 (0.0) 0 (0.0) 0 (0.0) 4 (9.8)
Bone pain 1 (2.4) 2 (4.9) 1 (2.4) 0 (0.0) 0 (0.0) 3 (7.3)
Haematuria 3 (7.3) 1 (2.4) 0 (0.0) 0 (0.0) 0 (0.0) 3 (7.3)
Inﬂuenza 2 (4.9) 2 (4.9) 0 (0.0) 0 (0.0) 0 (0.0) 3 (7.3)
Abdominal pain 2 (4.9) 1 (2.4) 0 (0.0) 0 (0.0) 0 (0.0) 3 (7.3)
Dysuria 3 (7.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (7.3)
Headache 3 (7.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (7.3)
Hot ﬂush 3 (7.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (7.3)
Hypertension 0 (0.0) 2 (4.9) 1 (2.4) 0 (0.0) 0 (0.0) 3 (7.3)
Rash 2 (4.9) 1 (2.4) 0 (0.0) 0 (0.0) 0 (0.0) 3 (7.3)
Rhinorrhoea 3 (7.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (7.3)
Vomiting 2 (4.9) 1 (2.4) 0 (0.0) 0 (0.0) 0 (0.0) 3 (7.3)
Prostate cancer 0 (0.0) 1 (2.4) 1 (2.4) 0 (0.0) 1 (2.4) 3 (7.3)
a AEs occurring in 5% of patients.
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without prior chemotherapy and CYP17i treatment
who received 1400 mg/d of ODM-201 were those who
showed the greatest PSA suppression [19]. ODM-201 dose
levels used in this study were based on the efficacy
observed in the main ARADES [19] and ARAFOR [20] trialsTable 3 – Treatment-related adverse events (TRAEs) a.
Patients reporting grade 1 TRAEs, n (%)
Any TRAE
ARADES (n = 11) 4 (36.4)
ARAFOR (n = 30) 6 (20.0)
Total (n = 41) 10 (24.4)
All TRAEs (n = 41)
Fatigue 3 (7.3)
Hot ﬂush 2 (4.9)
Abdominal pain 1 (2.4)
Constipation 1 (2.4)









Poor peripheral circulation 1 (2.4)
Solar dermatitis 1 (2.4)
Somnolence 1 (2.4)
Tinnitus 1 (2.4)
Urinary incontinence 1 (2.4)
a All TRAEs were of grade 1.in patients receiving higher doses of study medication, and
are consistent with the study design of two planned phase
3 ODM-201 trials, ARAMIS (NCT02200614) and ARASENS
(NCT02799602), in which patients will receive the 1200 mg
daily dose of ODM-201.
The ODM-201 safety profile after extended use is consis-
tent with data previously reported for the ARADES and
ARAFOR trials [19,20] and no additional safety concerns
were observed. Most patients analysed here (n = 32/41,
78.0%) experienced AEs of grade 1–2; likewise, in the main
ARAFOR and ARADES trials, most AEs (116/129, 90%, and
82/83, 99%, respectively) were of grade 1–2 among all the
AEs reported. Of these, the most common events were
fatigue (grade 1 in 8/41, 19.5%) and nausea (grade 1–3 in
5/41, 12.2%), which are clinically relevant AEs in mCRPC and
are commonly observed during treatment with AR antago-
nists [13,16,22–25]. The incidence of AEs in chemotherapy-
naïve and CYP17i-naïve patients analysed here is similar to
that reported in the same patient population during the
main ARADES and ARAFOR trials at the time of the original
cutoff dates, demonstrating that extended ODM-201 treat-
ment is not associated with any new safety concerns.
On the basis of these data, the safety of ODM-201 com-
pares favourably with that reported for other AR antago-
nists, such as enzalutamide, whose long-term safety profile
was established in chemotherapy-naïve patients in a phase
1/2 trial [23] from which patients with a known risk of
seizure were excluded. For both AR antagonists, the most
commonly reported treatment-emergent AEs following
extended treatment were fatigue and nausea, observed in
19.5% (grade 1 fatigue) and 12.2% (grade 1–3 nausea) of
Fig. 2 – (A) Prostate-specific antigen (PSA) percentage change from
baseline, by subject, truncated at +50%. (B) Maximum PSA percentage
change from baseline during study, by subject. (C) Time to PSA
progression. CI = confidence interval.
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men, fatigue occurred in 72% (any grade) of patients, with
15% experiencing grade 3/4, whereas nausea (any grade)
was reported by 31% of patients [23]. The incidence of
fatigue during extended ODM-201 treatment reported here
is also lower than that seen in phase 3 trials of enzalutamide
(36% all grades and 2% grade 3) [16] and abiraterone
acetate (39% all grades and 2% grade 3) [17] in patients
who had not received chemotherapy. Importantly, no
seizures were reported after extended treatment with
ODM-201. This may be explained by the lower likelihood
of ODM-201 crossing the blood-brain barrier, as shown inpreclinical studies, and may be related to the unique chem-
ical structure of ODM-201; additional trials are needed
to confirm these findings [18,26]. Prior enzalutamide
trials reported treatment-related seizures [13,23,24], and
preclinical studies suggested that enzalutamide may cross
the blood-brain barrier and bind to GABA receptors
[13,24,27,28], thereby increasing the risk of seizures.
In addition to a favourable tolerability profile, prolonged
treatment with ODM-201 provided sustained antitumour
activity: a decrease in PSA levels from baseline was main-
tained over time in most chemotherapy-naïve and CYP17i-
naïve patients at all doses tested (Fig. 2A,B), similar to the
ARADES and ARAFOR trials. The median times to PSA pro-
gression (12.4 mo, 95% CI 6.3–18.2) and radiological
progression (15.3 mo, 95% CI 9.5–NR) were similar to data
from the main ARAFOR trial (12.4 mo, 95% CI 5.3–NR; and
15.2 mo, 95% CI 9.4–18.2) but were shorter than those
reported for chemotherapy-naïve and CYP17i-naïve
patients from the ARADES main trial (16.6 mo, 95% CI
5.6–NR; and NR, 95% CI 8.4–NR).
A limitation of this analysis is that, being a non-random-
ised phase 1/2 trial, there was no control group and a
relatively small number of patients was included (n = 41).
Therefore, although multiple doses were tested, no defini-
tive conclusion may be drawn regarding the optimal effi-
cacy of each ODM-201 dose. Nevertheless, the promising
antitumour activity and favourable safety profile of ODM-
201 provide a basis for future confirmatory phase 3 trials
[29]. In this regard, the efficacy and safety of ODM-201 are
currently being evaluated in large placebo-controlled phase
3 trials among men with high-risk nonmetastatic CRPC
(ARAMIS, NCT02200614) and men with metastatic castra-
tion-sensitive prostate cancer (ARASENS, NCT02799602).
Another limitation is that QoL measurements were not
included during this follow-up analysis. As a spectrum of
neurocognitive psychological effects have been associated
with ADT and AR inhibitors, further studies are warranted
to assess the effect of extended ODM-201 treatment on
patient-reported QoL [30].
5. Conclusions
Extended treatment with ODM-201 at doses of 1200–
1800 mg/d continued to show encouraging antitumour
activity in patients with mCRPC who had not received prior
chemotherapy and CYP17i. No additional or unexpected
safety signals were observed beyond those reported at
the initial analysis points of the ARADES and ARAFOR trials.
ODM-201 may represent a well-tolerated and effective
treatment option for patients with mCRPC.
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